Three years after the ALLSTAR clinical trial ended prematurely, the study’s data shows that treatments of cardiosphere-derived cells — the same cells used as an experimental therapy tested in COVID-19 patients — demonstrated unexpected promise in heart attack survivors. Downloadable video available.